Plato Investment Management Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Plato Investment Management Ltd acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 3,671 shares of the biopharmaceutical company’s stock, valued at approximately $1,099,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. iA Global Asset Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 979.5% in the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after acquiring an additional 16,133 shares in the last quarter. SCS Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $34,784,000. Hussman Strategic Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $2,505,000. Hsbc Holdings PLC raised its position in shares of Alnylam Pharmaceuticals by 22.6% during the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after purchasing an additional 16,503 shares during the period. Finally, Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth $243,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $228.61 on Wednesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The firm has a 50-day moving average of $270.12 and a 200 day moving average of $299.25. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The firm has a market cap of $30.59 billion, a P/E ratio of 42.49 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business’s revenue was up 66.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.51) earnings per share. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Insider Buying and Selling

In other news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ALNY shares. Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective on the stock in a research note on Monday, August 3rd. Citigroup decreased their target price on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research report on Monday, August 3rd. Barclays lowered their target price on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Stifel Nicolaus cut their price target on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Finally, Wall Street Zen lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $393.86.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.